Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 26718501)

Published in Diabetes on December 30, 2015

Authors

Massimo Porta1, Iiro Toppila2, Niina Sandholm2, S Mohsen Hosseini3, Carol Forsblom2, Kustaa Hietala4, Lorenzo Borio1, Valma Harjutsalo5, Barbara E Klein6, Ronald Klein6, Andrew D Paterson3, DCCT/EDIC Research Group, Per-Henrik Groop7, FinnDiane Study Group

Author Affiliations

1: Department of Medical Sciences, University of Turin, Turin, Italy.
2: Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
3: Genetics and Genome Biology Program, Hospital for Sick Children, Toronto, Canada.
4: Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.
5: Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland National Institute for Health and Welfare, Helsinki, Finland.
6: Department Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI.
7: Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland Baker IDI Heart and Diabetes Institute, Melbourne, Australia per-henrik.groop@helsinki.fi.

Associated clinical trials:

Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893

Diabetes Control and Complications Trial (DCCT) | NCT00360815

Articles citing this

Genetics: Risk of microvascular complications of T1DM. Nat Rev Endocrinol (2016) 0.75

Progress in Defining the Genetic Basis of Diabetic Complications. Curr Diab Rep (2017) 0.75

Articles cited by this

PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92

Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics (2010) 21.21

Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics (2003) 17.92

The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Discovery and refinement of loci associated with lipid levels. Nat Genet (2013) 7.86

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA (2002) 6.61

Long-term complications of diabetes mellitus. N Engl J Med (1993) 5.36

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes (1996) 5.09

Validating, augmenting and refining genome-wide association signals. Nat Rev Genet (2009) 4.56

Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07

Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61

The structural and biochemical foundations of thiamin biosynthesis. Annu Rev Biochem (2009) 2.32

Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes (2003) 1.99

Epidemiology of proliferative diabetic retinopathy. Diabetes Care (1992) 1.91

Molecular mechanisms of thiamine utilization. Curr Mol Med (2001) 1.88

New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79

Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy. N Engl J Med (2009) 1.79

Biotin-responsive basal ganglia disease: a novel entity. Brain (1998) 1.74

Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia (1996) 1.70

The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl (2000) 1.69

High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia (2007) 1.39

SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta (2001) 1.32

Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab (2000) 1.31

BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet (2011) 1.28

Heritability of proliferative diabetic retinopathy. Diabetes (2008) 1.25

Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol (2004) 1.23

Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes (2004) 1.21

Thiamine intestinal transport and related issues: recent aspects. Proc Soc Exp Biol Med (2000) 1.14

Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem (2006) 1.13

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care (2010) 1.05

Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia (2008) 1.00

Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol (2013) 0.98

The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet (2014) 0.93

Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes Obes Metab (2011) 0.91

Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One (2012) 0.85

Articles by these authors

(truncated to the top 100)

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42

Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 3.16

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes (2009) 2.80

Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation (2009) 2.66

Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64

Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med (2017) 2.56

Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med (2011) 2.30

Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26

The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes (2006) 2.20

Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care (2011) 2.20

The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care (2011) 2.16

Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia (2011) 2.07

Leisure-time physical activity and development and progression of diabetic nephropathy in type 1 diabetes: the FinnDiane Study. Diabetologia (2015) 2.05

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04

The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation (2012) 1.92

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia (2011) 1.90

Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care (2009) 1.87

Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol (2011) 1.82

Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81

New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79

Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes (2013) 1.71

Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes (2011) 1.63

Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes (2008) 1.56

1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol (2008) 1.51

Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med (2012) 1.50

Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42

Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.42

Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes--indication of an increased environmental pressure? Diabetologia (2003) 1.41

Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care (2013) 1.39

Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes (2013) 1.37

Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes (2007) 1.34

Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes (2005) 1.34

Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.33

Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet (2012) 1.33

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes (2013) 1.31

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int (2003) 1.30

BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet (2011) 1.28

Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies. PLoS One (2009) 1.28

Heritability of proliferative diabetic retinopathy. Diabetes (2008) 1.25

Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes (2008) 1.20

Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation (2011) 1.20

DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep (2010) 1.18

Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care (2009) 1.18

Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis (2006) 1.15

Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care (2014) 1.15

Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol (2002) 1.13

Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes (2013) 1.11

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care (2017) 1.11

Health-related quality of life in patients with type 1 diabetes--association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant (2009) 1.10

Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes. Diabetologia (2010) 1.08

Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia (2007) 1.07

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care (2014) 1.07

The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care (2013) 1.07

Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care (2010) 1.05

Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia (2004) 1.05

Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum. MAGMA (2006) 1.04

Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care (2008) 1.04

Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes (2014) 1.01

Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens (2012) 1.01

Meta-analysis of genome-wide association studies in five cohorts reveals common variants in RBFOX1, a regulator of tissue-specific splicing, associated with refractive error. Hum Mol Genet (2013) 1.01

Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). J Am Coll Cardiol (2012) 1.00

Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther (2013) 1.00

Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med (2006) 0.98

Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia (2009) 0.98

Physical activity and diabetes complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Diabetes Care (2007) 0.98

Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care (2013) 0.98

GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia (2014) 0.97

High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol Dial Transplant (2011) 0.97

Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes (2013) 0.96

Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res (2002) 0.95

Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med (2015) 0.94

Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care (2010) 0.94

Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia (2006) 0.94

The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet (2014) 0.93

Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications (2005) 0.92

Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy? Diabetologia (2012) 0.92

Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women. Diabetologia (2007) 0.91

Arterial stiffness and vascular complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann Med (2010) 0.91

Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia (2009) 0.91

Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clin J Am Soc Nephrol (2010) 0.91

The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care (2013) 0.91

Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med (2009) 0.90

Increased levels of alpha-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy. Nephrol Dial Transplant (2007) 0.90

Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care (2014) 0.90

Energy and nutrient intakes and adherence to dietary guidelines among Finnish adults with type 1 diabetes. Ann Med (2010) 0.89

Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes (2013) 0.88

HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes. Diabetologia (2013) 0.88

Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications (2008) 0.88

Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. Diabetes Care (2007) 0.88

Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care (2013) 0.88

Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes (2011) 0.88

Polymorphisms in the nephrin gene and diabetic nephropathy in type 1 diabetic patients. Kidney Int (2003) 0.88

The genetic variant of lactase persistence C (-13910) T as a risk factor for type I and II diabetes in the Finnish population. Eur J Clin Nutr (2004) 0.87

Elevated MBL concentrations are not an indication of association between the MBL2 gene and type 1 diabetes or diabetic nephropathy. Diabetes (2009) 0.87

Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care (2013) 0.87

Pulse pressure predicts incident cardiovascular disease but not diabetic nephropathy in patients with type 1 diabetes (The FinnDiane Study). Diabetes Care (2011) 0.87

The AT2 gene may have a gender-specific effect on kidney function and pulse pressure in type I diabetic patients. Kidney Int (2006) 0.87

Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women: the FinnDiane study. Diabetes Care (2005) 0.86

Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy. Diabetes Care (2015) 0.86